Meredith Schultz

Meredith Schultz serves as the Vice President, Global Medical Expert for Gene Therapies at Ultragenyx since April 2025. Prior to this role, Meredith held the position of Chief Medical Officer at Taysha Gene Therapies from December 2023 to January 2025, overseeing management and business development. Earlier experience includes roles at Asklepios BioPharmaceutical, Inc. as Senior Vice President and Head of Clinical Development and Medical Affairs, and Vice President, Sector Lead for Early Stage AAV Gene Therapy Technology and Therapeutics from July 2021 to December 2023. Meredith's career also includes significant contributions at Novartis Gene Therapies and AveXis, Inc., focusing on clinical strategies for rare neurologic diseases. Educational credentials include a Master of Science in Individualized Genomics and Health from Johns Hopkins University and a Doctor of Medicine degree from the University of Wisconsin-Madison.